Jun 2026 (Q2 FY26) — Aug 17, 2026
InspireMD Q2 FY26 — Strategic Realignment Amidst Recall, Focus on Regulatory Milestones
Read the full callInspireMD (NSPR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
InspireMD earnings: last reported Mon, 17 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1.8 | −0.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -815.6 | −83.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -14.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.44 −4.35% · −$0.02
Performance −81.0% 1Y
1Y: $2.32 on 17 Oct 2025 → $0.44. High $2.35 (21 Oct 2025), low $0.44 (19 Oct 2026).
- Previous close
- $0.46
- 52-week range
- $0.44 – $2.35
- One year
- −81.20%
Overview
- Symbol
- NSPR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
InspireMD earnings calls (NSPR)
Financials
What the filings say
Net profit, year on year: −9% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 2 |
| Operating profit | -8 | -9 | -11 | -13 | -13 | -12 | -14 | -14 |
| Operating margin | −467.5% | −480.6% | −749.5% | −732.2% | −517.3% | −383.7% | −411.4% | −815.6% |
| Other income | 1 | 0 | 0 | -0 | 0 | 0 | 0 | 0 |
| Net profit | -8 | -9 | -11 | -13 | -13 | -12 | -14 | -14 |
| EPS ($ per share) | -0.16 | — | -0.22 | -0.26 | -0.17 | — | -0.16 | -0.17 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -148 | -158 | -168 | -183 | -202 | -222 | -254 | -302 |
| Total liabilities | 4 | 4 | 6 | 6 | 7 | 8 | 11 | 14 |
| Fixed assets | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 4 |
| Investments | — | — | — | — | — | 29 | 16 | 45 |
| Total assets | 12 | 10 | 18 | 40 | 25 | 48 | 47 | 69 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8 | -10 | -9 | -13 | -16 | -16 | -22 | -35 |
| Cash from investing | -0 | -0 | -0 | -22 | 8 | -16 | 13 | -31 |
| Cash from financing | 13 | 6 | 16 | 35 | -0 | 38 | 18 | 56 |
| Net cash flow | 6 | -4 | 7 | -1 | -7 | 5 | 9 | -10 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -2 |
| Free cash flow | -8 | -10 | -9 | -14 | -16 | -17 | -23 | -37 |
Insider filings
38 filings between Nov 12, 2025 and May 27, 2026.
Open market
decisions to buy or sellPurchases
$420.8K
15 purchases by 4 insiders
Sales
$127.0K
12 sales by 1 insider
Compensation
not trading decisions- 11
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Stuka Paul | $186.7K | — | May 27, 2026 |
| Gleason Shane Thomas | — | $127.0K | May 19, 2026 |
| ROUBIN GARY S | $106.2K | — | May 7, 2026 |
| Ward Scott R. | $102.6K | — | May 7, 2026 |
| Slosman Marvin | $25.2K | — | May 12, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | Stuka Paul Director | Purchase | 20,000 | $17.5K |
| May 19, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 22,778 | $23.0K |
| May 14, 2026 | Stuka Paul Director | Purchase | 5,000 | $5.8K |
| May 13, 2026 | Stuka Paul Director | Purchase | 10,000 | $11.6K |
| May 12, 2026 | Slosman Marvin CEO and President | Purchase | 21,000 | $25.2K |
| May 11, 2026 | Stuka Paul Director | Purchase | 10,000 | $11.9K |
| May 8, 2026 | Stuka Paul Director | Purchase | 65,626 | $76.1K |
| May 7, 2026 | ROUBIN GARY S Director | Purchase | 90,000 | $106.2K |
| May 7, 2026 | Ward Scott R. Director | Purchase | 73,255 | $84.2K |
| May 7, 2026 | Stuka Paul Director | Purchase | 6,378 | $7.3K |
| May 6, 2026 | Stuka Paul Director | Purchase | 1,517 | $1.7K |
| May 6, 2026 | Ward Scott R. Director | Purchase | 15,995 | $18.4K |
| Feb 2, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 2,941 | $4.7K |
| Feb 2, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 2,000 | $3.2K |
| Jan 30, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 2,900 | $4.7K |
| Jan 29, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 5,000 | $8.3K |
| Jan 28, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 12,395 | $20.5K |
| Jan 27, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 4,781 | $8.0K |
| Jan 22, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 8,411 | $13.2K |
| Jan 21, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 17,593 | $28.6K |
| Jan 20, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 2,955 | $4.7K |
| Jan 16, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 2,250 | $3.6K |
| Jan 15, 2026 | Gleason Shane Thomas Chief Commercial Officer | Sale | 2,909 | $4.6K |
| Jan 14, 2026 | Dearen Danny L. Director | Award | 44,030 | $0 |
| Jan 14, 2026 | Slosman Marvin CEO and President | Award | 1,114,792 | $0 |
| Jan 14, 2026 | ROUBIN GARY S Director | Award | 88,053 | $0 |
| Jan 14, 2026 | Lawless Michael A Chief Financial Officer | Award | 226,695 | $0 |
| Jan 14, 2026 | BERMAN MICHAEL Director | Award | 88,053 | $0 |
| Jan 14, 2026 | COHEN RAYMOND W Director | Award | 44,030 | $0 |
| Jan 14, 2026 | Gleason Shane Thomas Chief Commercial Officer | Award | 453,390 | $0 |
| Jan 14, 2026 | Ward Scott R. Director | Award | 88,053 | $0 |
| Jan 14, 2026 | Tommasoli Andrea Chief Operating Officer | Award | 226,695 | $0 |
| Jan 14, 2026 | Stuka Paul Director | Award | 132,076 | $0 |
| Dec 30, 2025 | Arnold Kathryn Director | Award | 55,556 | $0 |
| Dec 9, 2025 | Stuka Paul Director | Purchase | 2,710 | $4.9K |
| Dec 5, 2025 | Stuka Paul Director | Purchase | 5,073 | $9.4K |
| Dec 4, 2025 | Stuka Paul Director | Purchase | 10,130 | $18.7K |
| Nov 12, 2025 | Stuka Paul Director | Purchase | 13,431 | $21.8K |
| Oct 7, 2025 | ROUBIN GARY S Director | Award | 48,000 | $0 |
| Sep 15, 2025 | Kester Thomas J Director | Award | 37,815 | $0 |
| Jul 30, 2025 | Slosman Marvin CEO and President | Purchase | 10,330 | $25.0K |
| Jul 30, 2025 | Kester Thomas J Director | Purchase | 30,991 | $75.0K |
| Jul 30, 2025 | ROUBIN GARY S Director | Purchase | 41,322 | $100.0K |
| Jul 30, 2025 | Stuka Paul Director | Purchase | 20,661 | $50.0K |
| Jul 11, 2025 | Kester Thomas J Director | Option exercised | 30,624 | $42.3K |
| Jul 1, 2025 | Stuka Paul Director | Option exercised | 87,500 | $121.0K |
| Jun 29, 2025 | BERMAN MICHAEL Director | Option exercised | 61,248 | $84.7K |
| Jun 25, 2025 | ROUBIN GARY S Director | Option exercised | 30,624 | $42.3K |
| May 30, 2025 | Gleason Shane Thomas Chief Commercial Officer | Sale | 7,186 | $18.0K |
| May 29, 2025 | Gleason Shane Thomas Chief Commercial Officer | Sale | 3,760 | $9.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for InspireMD, Inc.
Free account. Everything above stays public.
Write why you follow InspireMD, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading